- Home
- ACRS vs AFRI Comparison
ACRS vs AFRI Comparison
Compare ACRS & AFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRS | AFRI |
|---|---|---|
| Founded | 2012 | 1943 |
| Country | United States | Gibraltar |
| Employees | N/A | 600 |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.0M | 269.1M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACRS | AFRI |
|---|---|---|
| Price | $4.34 | $9.90 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $10.20 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 11.1K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.01 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,683,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.34 | $7.47 |
| 52 Week High | $5.15 | $11.42 |
Technical Indicators
Market Signals| Indicator | ACRS | AFRI |
|---|---|---|
| Relative Strength Index (RSI) | 47.71 | 51.87 |
| Support Level | $4.15 | $9.80 |
| Resistance Level | $4.73 | $10.00 |
| Average True Range (ATR) | 0.24 | 0.26 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 39.64 | 37.93 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About AFRI Forafric Global PLC
Forafric Global PLC is engaged in the production and sale of wheat flour, semolina, pasta, and couscous products. The company operates through the Soft Wheat, Durum Wheat, and Couscous & Pasta segments. Its main brands include MAYMOUNA and TRIA. It generates the majority of its revenue from the Soft Wheat segment.